NASDAQ · Financial Statements

Catabasis Pharmaceuticals, Inc. (CATB) Financial Statements

$8.54 NASDAQ: CATB Market Cap $234.86M

Catabasis Pharmaceuticals, Inc. most recently reported annual revenue of $0, a net loss of $94.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Annual Financials (USD)

Metric2024
Revenue$0
Operating Profit$-112.0M
Net Profit$-94.0M
EPS$-1.68
Op Margin—

Balance Sheet (USD)

Metric2024
Total Assets$342.0M
Total Liabilities$23.0M
Cash$60.0M
Borrowings$5.0M

Cash Flow (USD)

Metric2024
Operating Cash Flow$-81.0M
Investing Cash Flow$-192.0M
Financing Cash Flow$157.0M
Net Cash Flow$-116.0M
Free Cash Flow$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-2.12
FCF Yield-29.35%
Quick Ratio10.78
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
CATB Overview CATB Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.